Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial

Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial

(2022) Maria Frånlund et al.   JOURNAL OF UROLOGY

Prostate-specific antigen (PSA) and biopsy contamination in the Göteborg-1 randomized, population-based, prostate cancer screening trial

(2022) K Stinesen Kollberg et al.   JOURNAL OF UROLOGY

Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study

(2021) Nathaniel Hendrix et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios

(2020) Abraham M. Getaneh et al.   Cancer Medicine

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

(2019) Jonas Hugosson et al.   EUROPEAN UROLOGY

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality

(2018) Richard M. Martin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Screening for Prostate Cancer

(2018) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Screening for Prostate Cancer Starting at Age 50–54 Years. A Population-based Cohort Study

(2017) Sigrid Carlsson et al.   EUROPEAN UROLOGY

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years

(2016) Paul F. Pinsky et al.   CANCER

The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer

(2016) Rebecka Arnsrud Godtman et al.   JOURNAL OF UROLOGY

The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening

(2016) Andrew J. Vickers et al.   UROLOGY

Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial

(2015) Rebecka Arnsrud Godtman et al.   EUROPEAN UROLOGY

Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia

(2015) Nandu D. Dantanarayana et al.   BMC Urology

Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies

(2013) Roman Gulati et al.   ANNALS OF INTERNAL MEDICINE

Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians

(2013) Amir Qaseem et al.   ANNALS OF INTERNAL MEDICINE

Early Detection of Prostate Cancer: AUA Guideline

(2013) H. Ballentine Carter et al.   JOURNAL OF UROLOGY

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

(2013) A. J. Vickers et al.   BMJ-British Medical Journal

Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality

(2012) Xiaoye Zhu et al.   JOURNAL OF MEDICAL SCREENING

Baseline Prostate-Specific Antigen Testing at a Young Age

(2011) Stacy Loeb et al.   EUROPEAN UROLOGY

Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden

(2010) Håkan Jonsson et al.   INTERNATIONAL JOURNAL OF CANCER

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

(2010) Jonas Hugosson et al.   LANCET ONCOLOGY

Screening and Prostate-Cancer Mortality in a Randomized European Study

(2009) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE